E C Pirog1, D S Heller, C Westhoff. 1. Department of Pathology, College of Physicians & Surgeons, Columbia University, New York, New York 10032, USA.
Abstract
OBJECTIVE: The objective was to examine why a proportion of patients with endometrioid adenocarcinoma (EMC) presents with advanced stage disease and whether the duration of bleeding prior to hysterectomy (treatment delay) is predictive of stage. STUDY DESIGN: A retrospective clinicopathologic study of 182 patients treated for EMC at Columbia-Presbyterian Medical Center in New York City between 1988 and 1996 was performed. RESULTS: Ninety percent of patients with EMC presented with abnormal uterine bleeding. The median time interval from onset of bleeding to biopsy diagnosis was 2.5 months (range, 2 weeks to 60 months) and 3 weeks from biopsy to hysterectomy. No correlation between the duration of symptoms and tumor stage was found (P = 0.87). There was, however, significant correlation between poor tumor differentiation and the advanced stage of the disease (P = 0.0001). CONCLUSIONS: Stage at presentation in patients with EMC correlates with tumor differentiation but not with time interval from bleeding to definitive therapy.
OBJECTIVE: The objective was to examine why a proportion of patients with endometrioid adenocarcinoma (EMC) presents with advanced stage disease and whether the duration of bleeding prior to hysterectomy (treatment delay) is predictive of stage. STUDY DESIGN: A retrospective clinicopathologic study of 182 patients treated for EMC at Columbia-Presbyterian Medical Center in New York City between 1988 and 1996 was performed. RESULTS: Ninety percent of patients with EMC presented with abnormal uterine bleeding. The median time interval from onset of bleeding to biopsy diagnosis was 2.5 months (range, 2 weeks to 60 months) and 3 weeks from biopsy to hysterectomy. No correlation between the duration of symptoms and tumor stage was found (P = 0.87). There was, however, significant correlation between poor tumor differentiation and the advanced stage of the disease (P = 0.0001). CONCLUSIONS: Stage at presentation in patients with EMC correlates with tumor differentiation but not with time interval from bleeding to definitive therapy.
Authors: Terri Madison; David Schottenfeld; Sherman A James; Ann G Schwartz; Stephen B Gruber Journal: Am J Public Health Date: 2004-12 Impact factor: 9.308
Authors: Antonieta Medina-Lara; Bogdan Grigore; Ruth Lewis; Jaime Peters; Sarah Price; Paolo Landa; Sophie Robinson; Richard Neal; William Hamilton; Anne E Spencer Journal: Health Technol Assess Date: 2020-11 Impact factor: 4.014
Authors: R D Neal; P Tharmanathan; B France; N U Din; S Cotton; J Fallon-Ferguson; W Hamilton; A Hendry; M Hendry; R Lewis; U Macleod; E D Mitchell; M Pickett; T Rai; K Shaw; N Stuart; M L Tørring; C Wilkinson; B Williams; N Williams; J Emery Journal: Br J Cancer Date: 2015-03-31 Impact factor: 7.640